A Phase 2 interventional study of SEP-363856 and Placebo capsule in Parkinson Disease Psychosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 24 sites in United States. Open to participants aged 55 Years to 105 Years. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Parkinson Disease · Otsuka Holdings Co., Ltd..
Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 2, and was the 12th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd. is open now. The open studies under Parkinson Disease, anywhere →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 55 Years to 105 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 143 across the 11 interventional studies, 5,290 across the 1 observational. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety and tolerability of SEP-363856 in subjects with Parkinson's Disease Psychosis. This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson's Disease. This study will be conducted in 24 study centers in the United States.
The study will last approximately 21 weeks.
This is a multicenter, randomized, parallel-group, placebo-controlled study evaluating the efficacy, safety, and tolerability of double-blind SEP-363856 flexibly dosed at 25, 50, or 75 mg/day for 6 weeks followed by 12 weeks of open-label extension of SEP-363856 flexibly-dosed at 25, 50, or 75 mg/day in male and female subjects ≥ 55 years of age with a clinical diagnosis of PDP. The study will randomize approximately 36 subjects to 2 treatment groups in a 2:1 ratio (approximately 24 subjects to SEP-363856 and 12 to placebo). The study will consist of 4 periods: Screening/Washout Period (up to 14 days prior to Double-blind Treatment), Double-blind Treatment Period (6 weeks), Open-label SEP-363856 Treatment Period (12 weeks), and Follow-up Period (1 week after last dose) as shown in the following figure. All postBaseline clinic visits will have a window of ± 2 days relative to the date of the Baseline visit (Visit 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Continuation into Open-label Extension Cirteria
Subject has not taken any medication other than the study drug for the purpose of controlling PDD symptoms
. • There has been no clinically significant change in the subject's medical condition or Parkinson's disease, in the opinion of the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SEP-363856 (25, 50, or 75mg/day), once daily
Drug: SEP-363856
Placebo once daily
Drug: Placebo capsule
SEP-363856 (25, 50, or 75mg/day)
Placebo once daily
Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6
There are seven items assessing individual symptoms (four items for hallucinations and three items for delusions), a global hallucinations item and a global delusions item. Separate items are rated from 0 (absent) to 5 (severe), so that higher values represent a worse outcome. Total score is equal to the sum of the seven items plus the global hallucinations, plus the global delusions. Therefore a total possible score on the SAPS-PD ranges from 0 to 45. The primary analysis of the primary efficacy variable will use a mixed model for repeated measures (MMRM).
Time frame: SAPS-PD assessments during DB treatment period, Baseline and Week 6
Change From Double Blind (DB) Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) at Week 6.
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. Analysis Method: Mixed Model Repeated Measures (MMRM)
Time frame: CGI-S assessments during DB treatment period, Baseline and Week 6
Change From Double Blind (DB) Baseline in Neuropsychiatric Inventory (NPI) at Week 6
The NPI is a 12-item behavior rating scale composed of a structured interview of the caregiver, which assesses psychiatric disturbance. For each subdomain, both the frequency (0 to 3 scale) and the severity (0 to 4 scale) of symptoms is determined. Higher scores represent a worse outcome. The subdomain score is the product of these two measures and ranges from 0 to 12. The combined NPI score is obtained by summing all 12 sub-domain scores and therefore ranges from 0 to 144. Analysis Method: Mixed Model Repeated Measures (MMRM)
Time frame: NPI assessments during DB treatment period, Baseline and Week 6
Change From Double-blind (DB) Baseline in Mini Mental State Evaluation (MMSE) at Week 6
The Mini Mental State Examination (MMSE) for Cognition is a brief instrument, used to assess cognitive function, consisting of 11 tests including orientation, memory (recent and immediate), concentration, language, and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. MMSE, the total score is the sum of all 11 tests. Analysis Method: Mixed Model Repeated Measures (MMRM)
Time frame: MMSE assessments during DB treatment period, Baseline and Week 6
| Milestone | Placebo | SEP-363856 |
|---|---|---|
| Started | 14 | 25 |
| Modified intent-to-treat population | 14 | 24 |
| Completed | 10 | 11 |
| Not completed | 4 | 14 |
| Withdrew: Adverse event | 1 | 6 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 5 |
| Withdrew: Withdrawal by pi due to other underlying illnesses | 0 | 1 |
| Milestone | Placebo | SEP-363856 |
|---|---|---|
| Started | 14 | 25 |
| Modified intent-to-treat population | 14 | 24 |
| Completed | 11 | 15 |
| Not completed | 3 | 10 |
| Withdrew: Adverse event | 1 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Withdrawal by pi due to other underlying illnesses | 0 | 1 |
| Milestone | Placebo | SEP-363856 |
|---|---|---|
| Started | 7 | 9 |
| Completed | 6 | 5 |
| Not completed | 1 | 4 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
There are seven items assessing individual symptoms (four items for hallucinations and three items for delusions), a global hallucinations item and a global delusions item. Separate items are rated from 0 (absent) to 5 (severe), so that higher values represent a worse outcome. Total score is equal to the sum of the seven items plus the global hallucinations, plus the global delusions. Therefore a total possible score on the SAPS-PD ranges from 0 to 45. The primary analysis of the primary efficacy variable will use a mixed model for repeated measures (MMRM).
| Units on a scale | Placebo | SEP-363856 |
|---|---|---|
| Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6 | -1.4 (-5.6 to 2.8) | -2.5 (-5.8 to 0.8) |
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. Analysis Method: Mixed Model Repeated Measures (MMRM)
| Units on a scale | Placebo | SEP-363856 |
|---|---|---|
| Change From Double Blind (DB) Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) at Week 6. | -0.7 (-1.5 to 0.1) | -0.4 (-1.1 to 0.3) |
The NPI is a 12-item behavior rating scale composed of a structured interview of the caregiver, which assesses psychiatric disturbance. For each subdomain, both the frequency (0 to 3 scale) and the severity (0 to 4 scale) of symptoms is determined. Higher scores represent a worse outcome. The subdomain score is the product of these two measures and ranges from 0 to 12. The combined NPI score is obtained by summing all 12 sub-domain scores and therefore ranges from 0 to 144. Analysis Method: Mixed Model Repeated Measures (MMRM)
| Units on a scale | Placebo | SEP-363856 |
|---|---|---|
| Change From Double Blind (DB) Baseline in Neuropsychiatric Inventory (NPI) at Week 6 | -17.3 (-28.3 to -6.2) | -11.5 (-20.2 to -2.8) |
The Mini Mental State Examination (MMSE) for Cognition is a brief instrument, used to assess cognitive function, consisting of 11 tests including orientation, memory (recent and immediate), concentration, language, and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. MMSE, the total score is the sum of all 11 tests. Analysis Method: Mixed Model Repeated Measures (MMRM)
| Units on a scale | Placebo | SEP-363856 |
|---|---|---|
| Change From Double-blind (DB) Baseline in Mini Mental State Evaluation (MMSE) at Week 6 | 0.3 (-0.9 to 1.4) | -0.8 (-1.7 to 0.2) |
Collected over All adverse events (AEs) during the 6-week DB and 12-week OL periods by actual treatment group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| SEP-363856 | 0/32 (0%) | 2/32 (6.3%) | 22/32 (68.8%) |
| Event | Placebo | SEP-363856 |
|---|---|---|
| Hip fractureInjury, poisoning and procedural complications | 0/14 | 1/32 |
| Mental disorderPsychiatric disorders | 0/14 | 1/32 |
| Event | Placebo | SEP-363856 |
|---|---|---|
| HallucinationPsychiatric disorders | 2/14 | 7/32 |
| FallInjury, poisoning and procedural complications | 3/14 | 6/32 |
| DizzinessNervous system disorders | 1/14 | 6/32 |
| Confusional statePsychiatric disorders | 2/14 | 5/32 |
| FatigueGeneral disorders | 2/14 | 2/32 |
| HypertensionVascular disorders | 2/14 | 2/32 |
| NauseaGastrointestinal disorders | 1/14 | 4/32 |
| SomnolenceNervous system disorders | 0/14 | 3/32 |
| AnxietyPsychiatric disorders | 0/14 | 3/32 |
| DelusionPsychiatric disorders | 0/14 | 3/32 |
| Age, Categorical(Participants) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 5 | 7 |
| >=65 years | 12 | 20 | 32 |
| Age, Continuous(Years) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| Mean | 71.8 ± 7.12 | 70.4 ± 7.31 | 70.9 ± 7.18 |
| Sex: Female, Male(Participants) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| Female | 1 | 4 | 5 |
| Male | 13 | 21 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 11 | 24 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| White | 12 | 24 | 36 |
| Asian | 0 | 1 | 1 |
| Other | 1 | 0 | 1 |
| Age, Customized(Participants) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| >=55 - <65 years | 2 | 5 | 7 |
| >=65 - <75 years | 7 | 12 | 19 |
| >=75 years | 5 | 8 | 13 |
| Baseline Body Mass Index (BMI) (kg/m^2)(kg/m^2) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| Mean | 24.15 ± 5.239 | 26.08 ± 4.808 | 25.42 ± 4.975 |
| Baseline Body Mass Index (BMI) Category(Participants) | Placebo | SEP-363856 | Total |
|---|---|---|---|
| <18.5 kg/m^2 | 1 | 1 | 2 |
| >=18.5 - <25.0 kg/m^2 | 7 | 8 | 15 |
| >=25.0 - <30.0 kg/m^2 | 3 | 14 | 17 |
| >=30.0 kg/m^2 | 2 | 2 | 4 |
| Missing | 1 | 0 | 1 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Dec 2016 to primary completion in Apr 2020, 39 months.
Results were first posted in Jun 2023, 3 years 1 month after primary completion. A results delay was requested in Apr 2021.
Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 39 months is above that.
Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc. →